CurrentEndo — Pediatric endocrinology

Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6–8 With Central Precocious Puberty

2026-11-13T17:00:16.153Z

Cross-sectional study · Clin Endocrinol (Oxf), 2026.

Growth Hormone Stimulation Testing in Childhood: Diagnostic Pathways and Discordant Results in a Tertiary Centre Cohort

2026-11-13T17:00:16.153Z

Diagnostic or prognostic study · Clin Endocrinol (Oxf), 2026.

Al-Gazali Skeletal Dysplasia Constitutes the Lethal End of ADAMTSL2-Related Disorders

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. Genetic etiology of Al-Gazali skeletal dysplasia: Compound heterozygous for pathogenic ADAMTSL2 variants 6 individuals

Identification of GNAS Variants in Circulating Cell‐Free DNA from Patients with Fibrous Dysplasia/ McCune Albright Syndrome

2026-11-13T10:57:18.358Z

Diagnostic or prognostic study · J Bone Miner Res, 2023. Detection of GNAS R201 variants in ccfDNA: R201 variants detected by either castPCR or ddPCR 41 of 66 (62.1%)

Impaired Bone Architecture in Peripubertal Children With HIV, Despite Treatment With Antiretroviral Therapy: A Cross-Sectional Study From Zimbabwe

2026-11-13T10:57:18.358Z

Cross-sectional study · J Bone Miner Res, 2022. Bone architecture by HIV status, later puberty — CWH vs CWOH: HIV*puberty interaction (males; 4% CSA); HIV*puberty interaction p = 0.035

Reduction of New Heterotopic Ossification ( HO ) in the Open‐Label , Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva ( FOP )

2026-11-13T10:57:18.358Z

Research article · J Bone Miner Res, 2023. New HO volume, 18 months — MOVE vs NHS: probability of any reduction (Bayesian compound Poisson model (BcPM) without transformation) 99.4%; with transformation: 65.4%

Divergent metabolic phenotypes in two genetic syndromes of low insulin secretion

2026-11-13T10:35:20.262Z

Cross-sectional study · Diabetes Res Clin Pract, 2022. Metabolic phenotype (body composition, adipokines, IGF axis, 5-hour oral glucose tolerance test (OGTT)): Both syndromic cohorts displayed DIS during OGTT

Approaches to Identify Factors Associated with Pubertal Timing in Self-Limited Delayed Puberty

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2022. Associations with pubertal timing: Correlation of pubertal timing with bone age p = 0.01

Children with Attention Deficit Hyperactivity Disorder Are More Likely to Fail Growth Hormone Stimulation Testing than Children without Attention Deficit Hyperactivity Disorder: A Retrospective Chart Review

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2022. Failed GHST — ADHD vs Without ADHD; p = 0.003; peak GH cut-off 10 ng/mL; more likely to fail with ADHD

Combined Arginine and Insulin Stimulation Elicits a Robust and Consistent Copeptin Response in Short Children

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2022. Serum copeptin concentration, 0, 60 and 90 min: Copeptin at 0 min (mean ± SD) 9.9 ± 5.0 pmol/L

Five-Year Therapy with Recombinant Human Insulin-Like Growth Factor-1 in a Patient with PAPP-A2 Deficiency

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2023. Growth on rhIGF-1 (P3), 5 years: Height velocity at baseline 3.0 cm/year

Growth Hormone Dose Modulation and Final Height in Short Children Born Small for Gestational Age: French Real-Life Data

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2023. last visit: Normal height SDS at last visit 193/291 (66.3%)

Molecular Genetic Analysis and Growth Hormone Treatment in a Three-Generation Chinese Family with Tricho-Rhino-Phalangeal Syndrome I

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2023. TRPS1 c.880_882delAAG variant identified in affected family members by whole-exome sequencing (WES) and Sanger sequencing

The Effect of a Nutritional Supplement on Growth and Body Composition in Short and Lean Preadolescent Boys following One Year of Intervention

2026-11-13T10:10:38.237Z

Randomized controlled trial · Horm Res Paediatr, 2022. Change in height-SDS, extension phase and 12 months — Good consumers vs Poor consumers; p = 0.028; extension phase; good consumers maintained height-SDS, poor consumers declined

The Effects of 5 Years of Growth Hormone Treatment on Growth and Body Composition in Patients with Temple Syndrome

2026-11-13T10:10:38.237Z

Cohort study · Horm Res Paediatr, 2023. Height SDS, 5 years of GH treatment: Mean height SDS increased significantly from -1.78 (95% CI -2.52; -1.04) to 0.11 (95% CI -0.66; 0.87)

Evaluation of cardiac structure, exercise capacity and electrocardiography parameters in children with partial and complete growth hormone deficiency and their changes with short term growth hormone replacement therapy

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2022. Left ventricular mass (LVM), before treatment and after 12 months of GH treatment — Complete GHD vs Healthy peers; p = 0.015; LVM lower before treatment in GHD

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency

2026-11-13T10:09:36.510Z

Meta-analysis · Pituitary, 2022. Changes from baseline in fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (HOMA-IR) and fasting insulin, GH-naïve patients, 34 and 86 weeks: GH-naïve (n = 120 somapacitan, n = 119 daily GH): higher changes from baseline in FPG, HOMA-IR and fasting insulin with daily GH vs somapacitan at 34 weeks, but not at 86 weeks

A Preliminary Analysis of Thyrotropin Measurement from Finger Stick Dried Blood Spot with an Automated High-Throughput Immunoassay Analyzer

2026-11-13T10:07:06.411Z

Diagnostic or prognostic study · Thyroid, 2023. Method comparison of TSH: venous plasma vs finger stick DBS: R2 0.988 (95% CI 0.986-0.990)

Meta-Analysis of DNA Methylation Datasets Shows Aberrant DNA Methylation of Thyroid Development or Function Genes in Down Syndrome

2026-11-13T10:07:06.411Z

Meta-analysis · Thyroid, 2022. Differential methylation of thyroid-related genes in DS: Discovery dataset: thyroid-related genes with significant associations for DS 18

Neonatal Screening for Congenital Hypothyroidism in Preterm Infants: Is a Targeted Strategy Required?

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. TSH by BW, first detection: BW <1000 g mean 2.08 ± 0.15 · BW 1001-1500 g mean 2.01 ± 0.02 · BW 1501-2499 g mean 2.28 ± 0.03 · Normal-weight mean 2.41 ± 0.03 mUI/L

Prevalence and Pathogenesis of Macro-Thyrotropin in Neonates: Analysis of Umbilical Cord Blood from 939 Neonates and Their Mothers

2026-11-13T10:07:06.411Z

Cross-sectional study · Thyroid, 2022. Macro-TSH prevalence in neonates (125I-TSH binding study): Neonates with significantly high 125I-TSH binding ratios (macro-TSH) 4 (0.43%)

Association of GDF15 levels with body mass index and endocrine status in β‐thalassaemia

2026-11-13T09:59:57.591Z

Cross-sectional study · Clin Endocrinol (Oxf), 2023. GDF15 and body mass index (BMI), IGF1 and reproductive hormones: GDF15 markedly elevated in β-thalassaemia major vs healthy controls 24.2-fold

Challenges in developing a quantitative method of measuring breast development using 3D imaging: An example of a novel method for use in induced breast development with exogenous oestrogen

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Intraobserver reproducibility with static image manipulation (intraclass correlation (ICC)) 0.77

Comparison of glucagon stimulation test and low dose ACTH test in assessing hypothalamic‐pituitary‐adrenal (HPA) axis in children

2026-11-13T09:59:57.591Z

Diagnostic or prognostic study · Clin Endocrinol (Oxf), 2023. Diagnostic accuracy of GST cortisol cut-offs for secondary AI: GST, cut-off 320 nmol/L: sensitivity 56%; specificity 83% · GST, cut-off 500 nmol/L: sensitivity 100%; specificity 6%

Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Height gain, end of treatment — ET vs LT; p = .065; greater in ET, not significant

Pre‐ and peripubertal sex steroids are inversely associated with birth weight in preterm boys

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Correlation of sex steroids with BW: Testosterone vs BW at 8 years (ρ) -0.35, p = .021

Serum kisspeptin, neurokinin B and inhibin B levels can be used as alternative parameters to distinguish idiopathic CPP from premature thelarche in the early stages of puberty

2026-11-13T09:59:57.591Z

Cross-sectional study · Clin Endocrinol (Oxf), 2023. Serum kisspeptin, NKB, INHB and AMH levels; differentiation of CPP from PT — CPP vs PT: AUC 0.819; p < .001; model of advanced bone age (BA), serum kisspeptin, NKB and INHB (multiple stepwise regression)

Undetectable anti‐Mullerian hormone and inhibin B do not preclude the presence of germ cell tumours in 45,X/46,XY or 46,XY gonadal dysgenesis

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Gonadoblastoma and/or dysgerminoma with undetectable AMH and inhibin B 3/11

Outcome after pediatric craniopharyngioma: the role of age at diagnosis and hypothalamic damage

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Outcome by age at diagnosis: Lower EFS but better QoL with age at diagnosis <6 years vs ≥6 years

Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study

2026-11-13T09:58:18.729Z

Randomized controlled trial · Eur J Endocrinol, 2023. Estimated mean annualised height velocity, 26 weeks: Somapacitan 0.16 mean 8.9 cm/year · Somapacitan 0.20 mean 11.0 cm/year · Somapacitan 0.24 mean 11.3 cm/year · Daily GH 0.035 mean 10.3 cm/year · Daily GH 0.067 mean 11.9 cm/year

Hyperinsulinemic Hypoglycemia Diagnosed in Childhood Can Be Monogenic

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. Monogenic cause identified: Childhood-onset 42 (24%) · Infancy-onset 1248 (74.5%)

Serum IGF-1 to IGFBP-3 Molar Ratio: A Promising Diagnostic Tool for Growth Hormone Deficiency in Children

2026-11-13T09:55:31.327Z

Diagnostic or prognostic study · J Clin Endocrinol Metab, 2022. Diagnostic performance for GHD: Low IGF-1/IGFBP-3 ratio: sensitivity 87.5%; specificity 83.0% · Low IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio: specificity 97.7% · Normal IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio: specificity for non-GHD cause of SS 100.0%

Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in SGA Children Treated With GH

2026-11-13T09:55:31.327Z

Cross-sectional study · J Clin Endocrinol Metab, 2022. Intraindividual tracking of IGF-I (SDS), ICC: Male ICC 0.50 (95% CI 0.47-0.53) · Female ICC 0.53 (CI 0.50-0.56)

Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study

2026-11-13T09:54:14.154Z

Cohort study · Lancet Diabetes Endocrinol, 2023. Annual incidence and annual linear trend, 2017-18: T1D 22.2 per 100 000; annual linear increase 2.02% (95% CI 1.54-2.49) · T2D 17.9 per 100 000; annual linear increase 5.31% (4.46-6.17)

Cord blood adiponectin and leptin concentrations in monochorionic twins with selective intrauterine growth restriction and their associations with childhood growth trajectories

2026-11-13T05:24:19.865Z

Cohort study · Pediatr Obes, 2023. birth — sIUGR vs Normal: β (adiponectin, association with IUGR) -1.51 (95% CI -2.45, -0.57); p = 0.002

Effect of Growth Hormone Therapy on Pubertal Timing: Systematic Review and Meta-Analysis

2026-11-13T04:57:29.624Z

Meta-analysis · Horm Res Paediatr, 2023. Pubertal timing, by clinical indication — rhGH vs Controls: mean difference -0.46 years (95% CI -0.90 to -0.03); ISS; age at pubertal timing; 9 studies; n total = 397

Evaluating Eating Behaviour, Energy Homeostasis, and Obesity in Childhood-Onset Craniopharyngioma: A Feasibility Study

2026-11-13T04:57:29.624Z

Research article · Horm Res Paediatr, 2023. Feasibility and acceptability: Included measures were deemed highly tolerable by participants and their parent/carers

Phenotype-Genotype Correlations of GH1 Gene Variants in Patients with Isolated Growth Hormone Deficiency or Multiple Pituitary Hormone Deficiency

2026-11-13T04:57:29.624Z

Cohort study · Horm Res Paediatr, 2023. IGHD IA due to homozygous whole GH1 gene deletion 1 patient

The Genetic Landscape of Children Born Small for Gestational Age with Persistent Short Stature

2026-11-13T04:57:29.624Z

Cohort study · Horm Res Paediatr, 2023. Genetic aetiology elucidated: Genetic aetiology elucidated 74/176 (42%)

Vascular Function and Intima-Media Thickness in Children and Adolescents with Growth Hormone Deficiency: Results from a Prospective Case-Control Study

2026-11-13T04:57:29.624Z

Case-control study · Horm Res Paediatr, 2023. Brachial FMD, baseline: GHD 8.75 ± 2.44 % · Controls 11.85 ± 5.98 %

Genetic testing can change diagnosis and treatment in children with congenital hypothyroidism

2026-11-13T04:56:16.556Z

Cohort study · Eur Thyroid J, 2023. Change in diagnosis after re-evaluation based on genetic testing: PCH changed to PHT n 2

Views on Short Stature of Female vs Male Endocrine Pediatric Patients Undergoing Provocative Growth Hormone Testing and Their Parents

2026-11-13T04:53:22.663Z

Research article · Endocr Pract, 2023. Patients' perceptions of their short stature were similar by gender

Clinical course of peripheral precocious puberty in girls due to autonomous ovarian cysts

2026-11-13T04:51:33.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Clinical course of ovarian cysts in PPP: Episodes of ovarian cysts 18

Congenital hypothyroidism in Northern Ireland: 40 years' experience of national screening programme

2026-11-13T04:51:33.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Incidence of CHT: Incidence of CHT in 1981 26 cases per 100,000 livebirths

Sex steroid priming for growth hormone stimulation testing in children and adolescents with short stature: A systematic review

2026-11-13T04:51:33.591Z

Meta-analysis · Clin Endocrinol (Oxf), 2022. GH response upon GHST: Studies indicating priming increases GH response upon GHST, increasing test specificity 9/15

Neonatal screening for congenital hypothyroidism in Sweden 1980-2013: effects of lowering the thyroid-stimulating hormone threshold

2026-11-13T04:50:20.257Z

Cohort study · Eur J Endocrinol, 2023. Incidence of CH after lowering the TSH screening threshold in 2009: Incidence of screening positive CH increased 1/3375 to 1/2222

Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial

2026-11-13T04:45:48.554Z

Randomized controlled trial · J Clin Endocrinol Metab, 2023. HQ-CT and CY-BOCS, 9.6 mg vs placebo, 8-week placebo-controlled period: Numeric improvements in both HQ-CT and CY-BOCS, not statistically significant

Clinical and Genetic Characterization of Familial Central Precocious Puberty

2026-11-13T04:45:48.554Z

Cohort study · J Clin Endocrinol Metab, 2023. Prevalence of familial CPP: Prevalence of familial CPP 22%

Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age

2026-11-13T04:45:48.554Z

Meta-analysis · J Clin Endocrinol Metab, 2022. Mean improvement in height SD score from baseline, 8 years of therapy: 2 to <4 years mean +2.5 · 4 to <6 years mean +2.2 · ≥6 years mean +1.7

Energy Trade-off and 4 Extreme Human Body Types

2026-11-13T04:45:48.554Z

Cohort study · J Clin Endocrinol Metab, 2022. ages 0.5-17.5 years: Two-hit pattern with profound changes during early infancy and at puberty for tall-slender and short-stout body types